American Association for Cancer Research

The American Association for Cancer Research (AACR) was formed in 1907 by professionals in the field of cancer research, treatment and academics. The objective of AACR is accelerate progress in the prevention, cure and treatment of cancer through research, education, communication and advocacy. The AACR Foundation is the fundraising component of AACR. Each year the AACR provides research grants to leading scientists and universities in the filed of cancer research. AACR publishes seven journals that run that gamut of cancer related research. These journals are; Cancer Research, Clinical Cancer Research, Molecular Cancer Therapeutics, Molecular Cancer Research, Cancer Epidemiology Biomarkers and Prevention, Cancer Prevention Research and CR Magazine. Each month AACR publishes up to six free abstracts of research funded by or supported by AACR. Additionally, AACR has a comprehensive on-line Cancer dictionary which includes the latest on the numerous varieties of cancers and treatments modalities. AACR is exceptionally open to the public and the media for inquiries about their work.

Address
615 Chestnut St., 17th Floor Philadelphia, PA 19106-4404
E-mail
jeremy.moore@aacr.org
Some content from Wikipedia, licensed under CC BY-SA

Marker may predict breast cancer response to tamoxifen

The presence of lower-than-normal amounts of the protein TGFBR2 was associated with breast cancer resistance to treatment with the antiestrogen therapeutic tamoxifen, according to a study published in Cancer Research, a journal ...

Apr 02, 2015
popularity27 comments 0

Prolonged statin use may lower risk of lung cancer death

Lung cancer patients who used statins in the year prior to a lung cancer diagnosis or after a lung cancer diagnosis had a reduction in the risk of death from the disease. The study results were published in Cancer Epidemiology, ...

May 01, 2015
popularity17 comments 0

Personalizing targeted immunotherapy

This year may indeed be the year in which a class of immunotherapeutics called PD-1 and PD-L1 inhibitors are approved for a variety of cancers, as forecast recently by Drew Pardoll, MD, PhD, in a blog post. There is huge ...

Apr 30, 2015
popularity5 comments 0